GSK says long-acting asthma treatment clears two Phase 3 studies

21 May 2024
endpts.com
Phase 3
GSK announced Tuesday morning that its experimental antibody treatment reduced the yearly rate of asthma attacks across two key clinical trials for adolescents and adults with a form of severe asthma.
The treatment, depemokimab, is a long-acting antibody that targets interleukin-5 (IL-5), a regulator of the body’s immune response. It’s the same target as GSK’s approved asthma drug Nucala, which generated £1.66 billion ($2.1 billion) in sales in 2023. While Nucala is dosed monthly, depemokimab can be dosed at six-month intervals.
GSK says long-acting asthma treatment clears two Phase 3 studies
Preview
Source: EndPoints
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
SIGN UP
LOG IN
BECOME A PREMIUM SUBSCRIBER
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
Drugs
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.